Didier Dargent

Didier Dargent holds extensive leadership experience in the biopharmaceutical and healthcare sectors, currently serving as Board Observer at PlasmidFactory GmbH, Board Member at Cube Biotech and Title21 Health Solutions, and Operating Partner at ArchiMed. Dargent's previous roles include Head of International Markets for Cell & Gene Therapy at Novartis Oncology, where a significant impact on growth and team development was made, and General Manager at Servier, managing substantial turnover and leading large teams in China. Dargent’s educational qualifications include dual Executive MBAs from INSEAD and Tsinghua University, a Master of Science in Pharmaceutical and Biotechnology Management from ESCP Business School, and a PhD in Pharmacy from Aix-Marseille University.